Sustained remission of chronic hepatitis C after a change to human leukocyte interferon-alpha in a difficult-to-treat patient with breakthrough phenomenon associated with antibodies against recombinant interferon-alpha [13]

American Journal of Gastroenterology

Volumn 96, Issue 2, 2001, Pages 612-614

  Berg, Thomas ^a   Schuff Werner, Peter ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALFANATIVE; ALPHA INTERFERON; HUMAN INTERFERON; INTERFERON ANTIBODY; LIVER ENZYME; NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA2A INTERFERON;

AGED; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; ENZYME BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LIVER HISTOLOGY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION;

EID: 0035124090     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)02372-8     Document Type: Letter

References (5)

1. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: Prevalence, etiology, and management
2. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C
3. Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C
4. Interferon antibodies and the breakthrough phenomenon during ribavirin interferon-combination therapy and interferon-monotherapy of patients with chronic hepatitis C
5. Randomized trial of interferon α2b plus ribavirin for 48 weeks or 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus